Re: Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al. Overall Survival with [177Lu]Lu-PSMA-617 Versus Cabazitaxel in Metastatic Castration-resistant Prostate Cancer (TheraP): Secondary Outcomes of a Randomised, Open-label, Phase 2 Trial. Lancet Oncol 2024;25:99–107

Autor: Xu, Jing, Ding, Li, Yang, Bin
Zdroj: European Urology Oncology; October 2024, Vol. 7 Issue: 5 p1150-1151, 2p
Databáze: Supplemental Index
Externí odkaz: